GW Pharmaceuticals stock soars due to optimistic Epidiolex Phase III results

14 March 2016

UK biopharma company GW Pharmaceuticals (AIM: GWP) has revealed positive findings in its Phase III study of Epidiolex (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and debilitating type of epilepsy.

Epidiolex achieved the study’s primary endpoint of significantly reducing convulsive seizures in children compared to placebo, the company announced on Monday, leading its stock price to rocket.

Treatment with the drug led to a median 39% reduction compared to 13% on placebo in what was the largest study ever conducted on Dravet syndrome. The average age of trial participants was 13 years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK